FDA Approves Rasonque, Revolution Medicines' First Drug, Amid Launch and Pricing Scrutiny

Key points

• FDA approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received prior therapy or are not candidates for multiagent systemic therapy.
• Phase III trial data showed a median overall survival of 13.2 months for Rasonque versus 6.7 months for chemotherapy, along with improved quality of life.
• The drug is priced at $39,800 per 30-day supply, with a new patient support program called OnPath offering $0 copays to aid access.
• Analysts project 2027 sales between $900 million and $1.76 billion, with some predicting it could be the fastest oncology launch in history.
• The approval does not require prior RAS mutation testing, potentially expanding eligibility, but the definition of 'not a candidate for multiagent therapy' remains undefined in prescribing information.

Background

This approval follows the announcement of pivotal Phase III trial results in April 2026 and a standing ovation at the American Society of Clinical Oncology meeting in May 2026. Prior to full commercial availability, the drug was accessible only through clinical trials and an Expanded Access Program (EAP).

How outlets are covering it

Fierce Pharma emphasizes the commercial and logistical challenges, noting that Revolution Medicines is a new company without the infrastructure of larger pharma giants, and highlighting the uncertainty surrounding the 'not a candidate for multiagent therapy' label. In contrast, the Pancreatic Cancer Action Network (PanCAN) frames the approval as a transformative, historic advance for a disease with a 13% five-year survival rate, focusing on patient empowerment and the shift from 'undruggable' RAS mutations to actionable targets. While Fierce questions the practicality of community outreach and insurance coverage, PanCAN stresses the immediate clinical benefit and the importance of biomarker testing for broader patient stratification.

Why it matters

Rasonque represents the first FDA-approved RAS inhibitor for pancreatic cancer, a disease with historically few treatment options. Its approval could redefine the standard of care, potentially shifting treatment from chemotherapy to targeted therapy earlier in the disease course, though access and pricing remain significant hurdles for widespread adoption.

What to watch

Revolution Medicines is transitioning patients from the Expanded Access Program to commercial supply, with the EAP portal closing shortly. The company is racing to prove Rasonque's superiority in first-line therapy to unlock its full blockbuster potential. Ongoing trials are also testing Rasonque in combination with chemotherapy and as adjuvant therapy after surgery to prevent recurrence.